Drug Repositioning and Target Finding Based on Clinical Evidence

Area of Science:

• Pharmacology
• Bioinformatics
• Drug Discovery

Background:

• Traditional drug development relies on gene-based strategies, leading to target molecule depletion.
• Gene-manipulated models and high-affinity ligands are current but limited approaches.

Purpose of the Study:

• To explore a novel drug-drug interaction hypothesis using clinical big data.
• To enable drug repositioning through a data-driven methodology.
• To identify and validate new drug targets via statistical analysis of adverse events.

Main Methods:

• Utilizing clinical big data for hypothesis generation.
• Statistical analysis and comparison of adverse event self-reports.
• Data-driven exploration of drug-drug interactions.

Main Results:

• Identification of new drug targets through analysis of adverse event data.
• Validation of drug repositioning hypotheses.
• Demonstration of a novel data-driven approach to drug discovery.

Conclusions:

• Clinical big data analysis of adverse events can uncover unexpected drug-drug interactions.
• This approach facilitates drug repositioning and overcomes limitations of traditional methods.
• The data-driven strategy is poised to influence future drug development and pharmaceutical research.